Clinical trials
catalyst calendar across sponsors →Studies where KNSA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
7 interventional · 1 observational · 3 with posted results
Held by 14 tracked-famous managers (Point72 Asset Management, L.P., D. E. Shaw & Co., Inc., TWO SIGMA INVESTMENTS, LP, AQR CAPITAL MANAGEMENT LLC, Balyasny Asset Management L.P., +9 more) · FINRA short interest 5.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult PatientsNCT04687358observationalPatients using 1 or more RP treatments | — | Active, not recruiting | — | Recurrent Pericarditis | 500 | Mar 2029 | ≤ 953 d | 2026-02-17 |
| Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387NCT07010159Phase 2: Time to Treatment Response by Week 24Randomized · Triple-masked · Treatment | Phase 2/3 | Recruiting | Drug: KPL-387, Placebo | Pericarditis, Pericarditis Acute, Recurrent Pericarditis | 325 | 2027-12-31 | in 497 d | 2026-08-11 |
| Transition to KPL-387 Monotherapy Dosing & Administration StudyNCT07288216Posology: Proportion of participants free from Pericarditis Recurrence by Week 16Non-randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: KPL-387 | Recurrent Pericarditis, Heart Diseases, Pericarditis | 80 | 2027-12-31 | in 497 d | 2026-08-11 |
| A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's DiseaseNCT06531395Change From Baseline in European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI) at Week 24Randomized · Quadruple-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Terminated due to strategic business decision. | Drug: Abiprubart, Placebo | Sjögrens Disease | 3 | 2025-03-06actual | — | 2025-05-21 |
| Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase InhibitorNCT05198310results2025-07-22Cohorts 1 and 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: KPL-404, Placebo | Arthritis, Rheumatoid | 145 | 2024-02-08actual | — | 2025-07-22 |
| Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammationNCT04447469results2025-01-22Cohort 1, Phase 2: Percentage of Participants Alive and Free of Mechanical Ventilation at Day 29Randomized · Double-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2/3 | Completed | Drug: mavrilimumab · Other: Placebo | COVID | 814 | 2021-11-12actual | — | 2025-01-22 |
| Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of KPL-404 in Healthy SubjectsNCT04497662TEAEs following IV dosingRandomized · Triple-masked · Other | Phase 1 | Completed | Drug: KPL-404 · Other: Matching Placebo | Healthy Volunteers | 52 | 2021-01-21actual | — | 2021-05-04 |
| KPL-301 for Subjects With Giant Cell ArteritisNCT03827018results2023-10-17Time to Flare by Week 26Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Combination product: mavrilimumab, placebo · Drug: prednisone | Giant Cell Arteritis | 70 | 2020-08-13actual | — | 2023-10-23 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19